Factors That Affect Attitude towards Generic Drugs’ Prescription: A Comparison of Pakistani and Slovenian General Practitioners’ Practices

Sohail Raza* and S. M. Shafi Azam
sohail.raza@gmail.com
SZABIST
Karachi, Pakistan

Abstract: Doctors are usually concerned about the quality of generic drugs, and possible liabilities connected with their use. Therefore, this study is an attempt to examine the attitudes of Pakistani General Practitioners (GPs) towards generic prescribing drugs. This study focuses on five areas that affect GPs’ prescribing habit of generic drugs. Moreover, this study evaluates and compares practices of GPs’ towards prescribe generic drugs in Pakistan and Slovenia. 50 General Practitioners are selected from Karachi through simple random sampling. Questionnaire—a primary data collection tool is used to collect data from all General Practitioners. The Slovenian study is used as secondary data source. MEGASTAT—a statistical package is used to conduct chi-square test of independence at 5% significance level. This study concludes that more academic details of generic drugs influence General Practitioners to prescribe them.

Keywords: Pharmaceutical, generic drugs, doctors, general practitioner

1. INTRODUCTION / BACKGROUND

Generics drugs, in general, are pharmaceutical products usually intended to be exchangeable with the research drugs, marketed after the expiry of patent or other exclusivity rights and usually manufactured without a license from the innovator company. This large category includes pharmaceuticals that were formerly patent protected, but whose patent has expired [1].

In Pakistan, many generic drugs launched before the launch of originator “innovator medicine”; like Lowplat launched by PharmEvo, generic version of Sanofi-Aventis Plavix, Hilton Pharma launched Piozer, generic version of Actos by Eli Lilly; Hilton also launched Lefora, generic version of Sanofi-Aventis Arava. In other cases, just after launch of original brand or after few new years, branded drugs were launched.

Total 106,463 of doctors registered at Pakistan Medical & Dental Association (PMDC) up to June 2007, registered as Registered Medical Practitioners (RMP), practicing at different places under different capacities [3]. General practitioners contributed 60% of all prescription in Pakistan, while doctors working under hospital environment contribute 30% of prescription & consultants contribute 10% of all prescriptions in Pakistan [4].

Healthcare organizations find a further way to reduce drug costs is to encourage the prescribing physicians to change their behavior. Roughly, every other physician prescribes both types of drugs, with some preferring generics and other branded products [5], [6]. Even in the absence of sound clinical research evidence, physicians usually yield to marketing pressure from the pharmaceutical industry [7].

Fewer interventions have successfully encouraged physicians to modify their prescribing practice [8], [9]. Prescribing generic drugs is one of the most frequently used prescribing indicators in General Practitioners segment in many countries [10]; also in third world countries like Pakistan, India, Bangladesh and Srilanka.

Analyzing the attitude of GPs towards generic drugs in Spain, about generic drugs, their prescribing habits, and the impact of prescribing generic drugs on health expenditure; and what they thought a generic drug should be [11]. Another one is from Slovenia surveyed 200 GPs out of 800 GPs from the National Health Insurance Institute database [12]. In Slovenia, generics command 45% market share, same as of Pakistan market share of generic drugs, continuously increasing reach to 49%.

* Working at Coats Pakistan & student of MS (MS) at SZABIST

Journal of Independent Studies and Research (JISR) - Management and Social Sciences & Economics
Volume 6, Number 2, July 2008

63
2. OBJECTIVE OF STUDY

General Practitioners are usually concerned about the quality of generic drugs, and possible liabilities associated with their use, despite of the healthcare professionals. Therefore, we wanted to examine the attitudes of Pakistani GPs towards generic prescribing. The findings should enable us to know the exact reasoning of GP attitude towards generic drugs prescription and compare research finding with the other studies conducted in other parts of the world.

3. PROBLEM STATEMENT

To find out the practice of Pakistani General Practitioners towards prescribing generic drugs, and compare it with general practitioners attitude in other parts of the world.

3.1 Research Hypothesis

- **H₀₁:** There is no difference between doctors’ prescription and patient demand for drugs in both countries
- **H₁₁:** There is difference between doctors’ prescription and patient demand for drugs in both countries
- **H₀₂:** There is no difference between sources of information on drugs in both countries
- **H₁₂:** There is no difference between sources of information on drugs in both countries
- **H₀₃:** In both countries, GPs are used to prescribe generic drugs under same condition to the original one
- **H₁₃:** In both countries, GPs are used to prescribe generic drugs under different condition to the original one
- **H₀₄:** Pharmaceutical companies influence General Practitioner for prescribing generic drugs in similar manners
- **H₁₄:** Pharmaceutical companies influence General Practitioner for prescribing generic drugs in different manners
- **H₀₅:** Pharmaceutical companies provide unbiased data about drugs in both countries in similar way
- **H₁₅:** Pharmaceutical companies do not provide unbiased data about drugs in both countries in similar way

4. RESEARCH METHODOLOGY

A questionnaire is designed to ask questions about their knowledge regarding generic drugs, awareness of prescribing costs, price of generic drugs relative to branded drugs and attitude towards use of generic drugs.


We have used MEGASTAT statistical software to analyze data collected through questionnaire and compare it with Slovenian study. Inferential Statistics used & Chi-squared test done for group comparison at significance of 0.05.

5. DATA ANALYSIS

a) Patient’s demands for drugs by defined drug name

<table>
<thead>
<tr>
<th></th>
<th>PAK</th>
<th>SLO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>32 (16.85)</td>
<td>2 (16.85)</td>
<td>34</td>
</tr>
<tr>
<td>Seldom</td>
<td>24 (33.37)</td>
<td>43 (33.37)</td>
<td>67</td>
</tr>
<tr>
<td>Usually</td>
<td>40 (39.66)</td>
<td>39 (39.66)</td>
<td>79</td>
</tr>
<tr>
<td>Always</td>
<td>2 (2.28)</td>
<td>3 (2.28)</td>
<td>5</td>
</tr>
<tr>
<td>Missing</td>
<td>2 (7.84)</td>
<td>14 (7.84)</td>
<td>16</td>
</tr>
</tbody>
</table>

**H₀₆:** There is no difference between doctors’ prescription and patient demand for drugs in both countries

**H₁₆:** There is difference between doctors’ prescription and patient demand for drugs in both countries
In this case, we reject Ho because Chi-square calculated 41.25 is greater than tabulated value of Chi-Square 9.488 in both countries, usually not followed patient’s demands for drugs by defined drug name.

Above graph clearly shows that Pakistani GPs not followed the patient’s demands for drugs by defined drug name, as 32% of GPs responded; while in case of Slovene General Practitioners, only 2% of GPs agreed that they never followed the patient’s demand of drug by name. Moreover, in case of seldom, 43% Slovenian General Practitioners seldom followed the patient’s demands of drug by name in case of this statistics, becomes 24%.

b) Where do patients get information on drugs

$$\chi^2 = 41.25, \text{ df} = 4, p = 2.39 \times 10^{-8}$$

In this case, we reject Ho because Chi-square calculated 41.25 is greater than tabulated value of Chi-Square 9.488 in both countries, usually not followed patient’s demands for drugs by defined drug name.

This graph also depicts that in Slovenia, patients are getting information mainly from their consultants and their friends (34% & 39% respectively); while in case of Pakistan, patients are getting information from their friends and waiting room at the General Practitioners Clinics (38% & 26 & respectively).

In case of other factors of information, from consultants 16%; media only 6%, as in Pakistan advertising on media is ban by the Ministry of Health for Ethical Drugs (Prescription Drugs that are prescribed by the doctors only); and from other GPs, 14% of patients are getting information about the drugs.

c) Condition in which GPs prefer to prescribing generic drugs

$$\chi^2 = 31.93, \text{ df} = 4, p = 1.98 \times 10^{-6}$$

In this case, we reject Ho because Chi-square calculated 31.93 is greater than tabulated value of Chi-Square 9.488 in both countries, in both countries patients are not getting information on drug from same source.

In both countries, GPs are used to prescribe generic drugs under same condition to the original one

<table>
<thead>
<tr>
<th>Source: This study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friends</strong></td>
</tr>
<tr>
<td><strong>PAK</strong></td>
</tr>
<tr>
<td><strong>SLO</strong></td>
</tr>
<tr>
<td><strong>Total</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Source: This study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>More academic detailing</strong></td>
</tr>
<tr>
<td><strong>PAK</strong></td>
</tr>
<tr>
<td><strong>SLO</strong></td>
</tr>
</tbody>
</table>

H_{A2}: There is no difference between sources of information on drugs in both countries

H_{A2}: There is no difference between sources of information on drugs in both countries

Table 2

<table>
<thead>
<tr>
<th></th>
<th>PAK</th>
<th>SLO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friends</td>
<td>38 (36.24)</td>
<td>34 (36.24)</td>
<td>72</td>
</tr>
<tr>
<td>Consultants</td>
<td>16 (27.54)</td>
<td>39 (27.54)</td>
<td>55</td>
</tr>
<tr>
<td>Media</td>
<td>6 (11.05)</td>
<td>16 (11.05)</td>
<td>22</td>
</tr>
</tbody>
</table>

Journal of Independent Studies and Research (JISR) - Management and Social Sciences & Economics
Volume 6, Number 2, July 2008
Table 3

<table>
<thead>
<tr>
<th></th>
<th>PAK</th>
<th>SLO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>More academic detailing</td>
<td>34 (35.49)</td>
<td>37 (35.49)</td>
<td>71</td>
</tr>
<tr>
<td>If generic drugs were cheaper</td>
<td>28 (29.10)</td>
<td>30 (29.10)</td>
<td>58</td>
</tr>
<tr>
<td>More clinical trials</td>
<td>24 (23.98)</td>
<td>24 (23.98)</td>
<td>48</td>
</tr>
<tr>
<td>Better marketing / availability</td>
<td>14 (11.43)</td>
<td>9 (11.43)</td>
<td>23</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

Source: This study

1.37 Chi-square
3 df
.7132 p-value
7.815 Tabulated Value

In this particular case, we accept Ho because Chi-Square calculated 1.37 is less than tabulated value of Chi-Square 7.815, means that in both countries, GPs used to prescribe generic drugs under same condition to the original one.

In both countries, general practitioners rated more to more academic detailing of the drugs (37% in case of Slovenia & 34% in case of Pakistan), second highest rated factor in prescribing generic drugs. If generic drugs were cheaper (30% & 28% respectively), followed by more clinical trial of these drugs conducted in the country (24% in both cases) lowest rated factors is the better marketing / availability of generic doctors (9% & 14%) compared to Slovenia, rated more to this particular factor.

d) Pharmaceutical companies influence in prescribing generic drugs

Hₐ₁: Pharmaceutical companies influence General Practitioner for prescribing generic drugs in similar manners

Hₐ₂: Pharmaceutical companies influence General Practitioner for prescribing generic drugs in different manners

Table 4

<table>
<thead>
<tr>
<th></th>
<th>PAK</th>
<th>SLO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No influence at all</td>
<td>40 (22.16)</td>
<td>4 (22.16)</td>
<td>44</td>
</tr>
<tr>
<td>Small influence</td>
<td>30 (23.62)</td>
<td>17 (23.62)</td>
<td>47</td>
</tr>
<tr>
<td>Considerable influence</td>
<td>28 (45.47)</td>
<td>63 (45.47)</td>
<td>91</td>
</tr>
<tr>
<td>Immense influence</td>
<td>2 (8.76)</td>
<td>16 (8.76)</td>
<td>18</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

Source: This study

56.04 Chi-square
3 df
4.12E-12 p-value
7.815 Tabulated Value

In this particular case, we reject Ho because Chi-Square calculated 56.04 is greater than tabulated value of Chi-Square 7.815, means both countries pharmaceutical companies influence General Practitioner for prescribing generic drugs in different manners.

In case of Pakistan, major General Practitioner was of the opinion that pharmaceutical companies do not influence, at all, to prescribe generic drugs, 40% compared to Slovenian case only 4%; while in case of small influence, 30% of GPs agreed that some companies, but small, influence in prescribing drugs. Moreover, Slovenian case major GPs (63% of sample) agreed that pharmaceutical companies, but considerable, influence on GPs to prescribe the generic drugs.

e) Unbiased data about drugs
H05: Pharmaceutical companies provide unbiased data about drugs in both countries in similar way

H15: Pharmaceutical companies do not provide unbiased data about drugs in both countries in similar way

Table 5

<table>
<thead>
<tr>
<th>Group</th>
<th>PAK</th>
<th>SLO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No one</td>
<td>20 (17.46)</td>
<td>15 (17.46)</td>
<td>35</td>
</tr>
<tr>
<td>Generic-drug companies</td>
<td>12 (16.09)</td>
<td>20 (1.09)</td>
<td>32</td>
</tr>
<tr>
<td>Brand-name drug companies</td>
<td>26 (18.26)</td>
<td>11 (18.26)</td>
<td>37</td>
</tr>
<tr>
<td>Both equally</td>
<td>42 (48.19)</td>
<td>54 (48.19)</td>
<td>96</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

Source: This study

10.97 Chi-square
3 df
.0119 p-value
7.815 Tabulated Value

In this case, we reject Ho because Chi-Square calculated 10.97 is greater than tabulated value 7.815.

General Practitioners in both countries agreed that both generic as well as branded “research” drug companies provide unbiased data of their drugs (42% in Pakistan & 54% Slovenian). In Pakistan, 26% of GPs was of opinion that branded name drug companies provide unbiased, compared to only 11% in Slovenian.

6. CONCLUSION

This study is an attempt to evaluate practice of General Practitioner to prescribe generic drugs in Pakistan and Slovenia. This study focuses five different areas, which influence doctors’ prescribing habit of generic drugs.

This research concludes that only a single area has similar practice between both countries, that is, General Practitioners preference to prescribe generic drugs is followed by details that are more academic.

In addition to above, generic drugs companies also conducted local trial of their drugs at private clinics / hospital level to show the effectiveness of their drugs, compared to the original drugs. Moreover, doctors rated better marketing/availability of the drugs at a lower scale.

Pharmaceutical companies in Slovenia put more pressure on the General Practitioner to prescribe the generic drugs.

As far as information provided by the pharmaceutical companies to the doctors, they agreed, in both countries, that both brand drugs as well as generic companies, provide unbiased data about drugs.

7. RECOMMENDATIONS

1. Major reason why GPs are ready to use generic drugs is the price difference between original drugs compared to generic drugs, so generic companies have to offer economical prices to doctors along with quality medicine.

2. Generic drugs companies have to make sure that they always used unbiased data for their drugs, that is not only beneficial for drugs but also position company as ethical company that always follow of pharmaceutical industry / medicine ethics for promoting their drugs to the doctors.

3. In Pakistan, many people used to take drugs without concerning any doctors, because people living around them used to give them advice to use particular drugs for particular illness, as they also had these drugs in past to treat their illness. Here, Ministry of Health’s role comes in; they have to restrict pharmacies for not providing any drugs without doctor’s prescription, as it is a practice in European countries as well as in North America. Only, Over the Counter (OTC) drug is allowed to the patient without having any prescription, as OTC already passed safety criteria of MOH.

4. Nowadays, generic drugs companies also conduct local trial of their drugs at doctors / hospital level to show the effectiveness of their drugs compared to the original drugs, resulting an increase in the confidence of the doctors to prescribe the generic drugs to their patients in many diseases. Even
now, doctors are prescribing generic version of drugs in chronic disease, as well, they have to increase this practice.

5. As far as information provided by the pharmaceutical companies, the doctors agreed in both countries that, both, brand drugs as well as generic companies provide unbiased data about drugs, most of the times to doctors. While, in case of Pakistan, General Practitioner rated branded drugs companies more than generic; while in case of Slovenia, General Practitioner are on greater extend agreed to Generic drugs companies which provide unbiased data on their drugs. All pharmaceutical companies, especially generic drugs companies, make sure that whatever information is provided to doctors must be supported by the valid source, so that anyone in healthcare can check, it if they want.

REFERENCES


[3] PMDC: Total number of doctors / dental surgeons (GP’s) registered up to 30th June 2007.


